Lairmore, Michael

Michael Dale Lairmore, DVM, PhD, Diplomate ACVP & ACVM, is Professor and Chair of the Department of Veterinary Biosciences in the College of Veterinary Medicine and the Associate Director for Basic Sciences in the Comprehensive Cancer Center. Dr. Lairmore is also Professor of Molecular Virology, Immunology and Medical Genetics. He joined the faculty in 1990. He is a member of the Integrated Biomedical Science Graduate Program; Molecular, Cellular, and Developmental Biology Graduate Program; Dorothy M. Davis Heart and Lung Research Institute; Comprehensive Cancer Center, The Arthur James Cancer Hospital and Research Institute; and the Center for Retrovirus Research. He is the recipient of numerous academic awards and earned the rank of Fellow of the American Association for the Advancement of Sciences (AAAS) in 2005. 

Human T-lymphotropic virus type 1 (HTLV-1) infection causes adult T-cell leukemia/lymphoma (ATL) and a variety of immune-mediated disorders. Dr. Lairmore's research seeks to understand mechanisms by which these proteins influence HTLV-1 replication and cellular gene expression during the natural infection. In addition, Dr. Lairmore serves as Program Director for a developing program of projects grant application supported through a cooperative relationship with The Ohio State University, Comprehensive Cancer Center.  The grant application is entitled, "Retrovirus Models of Lymphocyte Transformation and Disease".  The study of regulatory and accessory proteins and virus encoded enzymes of complex retroviruses such as human T-lymphotropic virus type 1 (HTLV-1) and human immunodeficiency virus (HIV) have provided fundamental knowledge to define mechanisms of viral-induced transformation and basic paradigms of cell biology. This Program Project Grant (PPG) application is focused on using retrovirus models to elucidate basic cellular mechanisms that determine lymphocyte transformation or associated lymphoproliferative disease.  The goals of this PPG are aligned and highly supportive of recently stated priorities of the National Cancer Institute (NCI) in Cancer Biology.   The proposed PPG is designed to foster each of the participant laboratories interactions and promote each to study mechanisms that allow retroviruses to exploit their cellular environment during replication. These findings will support efforts to further define therapeutic modalities against retroviral-induced lymphoma and its paraneoplastic syndromes (e.g., hypercalcemia and bone resorbtion). Each project within this PPG application shares the overall common goal to elucidate mechanisms of retrovirus-mediated lymphoproliferative disease.

Selected Publications

Kim S-J, Ding W, Albrecht B, Green P, and Lairmore. M. A. Conserved Calcineurin-binding Motif in HTLV-1 p12I Functions to Modulate NFAT Activation. J.Biol.Chem. 278: 15550-15557, 2003.

Ding W, Kim, Nair R, Michael B, Boris-Lawrie K, Tripp A, Feuer G, Lairmore M. HTLV-1 p12I Enhances Interleukin-2 Production During T cell Activation.  J.Virol. 77:11027-11039. 2003.
Holschu H LaPierre L, and Lairmore M.  Comparative Pathogenesis of Epsilonretroviruses. J. Virol. 77 12385-12391, 2003. 

Michael B, Nair A, Hiraragi H, Shen L, Feuer G, Boris-Lawrie K, and Lairmore M. HTLV-1 p30(II) alters cellular gene expression to enhance signaling pathways that activate T lymphocytes. Retrovirology 2004, 1:39, 2004.

Silic-Benussi M, Cavallari I, Zorzan T, Rossi E, Hiraragi H, Rosato A, Saggioro D, Lairmore M, Willems L, Chieco-Bianchi L, D'Agostino D, and Ciminale V. Suppression of Tumor Growth and Cell Proliferation by p13II, a Mitochondrial Protein of HTLV-1. Proc. Natl. Acad. Sci. USA. 101:6629-6634, 2004.

Michael B, Nair A, Lairmore M. Role of Accessory Proteins of HTLV-1 in Viral Replication, T Cell Activation, and Cellular Gene Expression. Frontiers in Biosciences 9: 2556-2576, 2004.

Younis I, Khair L, Nicot C, Franchini G, Lairmore M, and Green P. HTLV-1 and 2 ORF II Accessory Protein Induce Latency by a Novel Post Transcriptional Mechanism. J.Virol. 78:11077-11083. 2004.

Silverman L, Phipps A, Montgomery A, Ratner L, and Lairmore M. HTLV-1 Open Reading Frame II Encoded p30II is Required for In Vivo Replication: Evidence of In Vivo Reversion. J.Virol. 78:3837-3845, 2004.

Nair A,, Michael B, Hiraragi H, Fernandez S, Feuer G, Boris-Lawrie K and Lairmore M. HTLV-1 Accessory Protein p12I Modulates Cellular Gene Expression and Enhances p300 Expression in T Lymphocytes. AIDS Res. Human Retrov. 21:273-284, 2005.

Richard V, Nadella P, Luchin A, Green P, Lairmore M, Foley G, and Rosol T. Transcriptional Regulation of PTHrP Promotor P3 by ETS-1 in Adult T-Cell Leukemia /Lymphoma. Leukemia 19(7):1175-83, 2005.

Hiraragi H, Michael B, Nair A, Fernandez S, Silic-Benussi M, Ciminale V,  and Lairmore M.  HTLV-1 Mitochondria Localizing Protein p13II Sensitizes Jurkat T Cells o Ras-mediated Apoptosis J.Virol. 79: 9449-9457, 2005.

Silverman L, Phipps A, Montgomery A, Fernandez S, Tsukahara T, Ratner L, and Lairmore M. In Vivo Analysis of Replication and Immunogenicity of Proviral Clones of HTLV-1 with Selective Envelope Surface Unit Mutations. Blood 106:3602-3608, 2005.

Hiraragi H, Kim S-J, Phipps A, Silic-Benussi M, Ciminale V, Ratner L, Green P, and Lairmore M. HTLV-1 Mitochondria Localizing Protein p13II is Required for Viral Infectivity in vivo.J.Virol. 80:3469-3476, 2006.

Kim S-J, Nair AM, Fernandez S, Mathes L, and Lairmore M. Enhancement of LFA-1-Mediated T-Cell Adhesion by HTLV-1 p12I.  J.Immunol. 176(9):5463-5470, 2006.

Arnold J, Yamamoto B, Phipps AJ, Lairmore M, Green PL. HTLV-1 1 nuclear b-ZIP (HBZ) is dispensable for cellular immortalization In Vitro and viral spread and persistence in inoculated rabbits. Blood 107(10):3976-82, 2006.

Nair A, Michael B, Fernandez S, and Lairmore M. Calcium-dependent Enhancement of Transcription of p300 by Human T Lymphotropic Virus Type-1 p12I. Virology 353:247-257, 2006.

Michael B, Nair A, Hiraragi H, Datta A, Ratner L and Lairmore M. Histone Acetyltransferase (HAT) Activity of p30 Modulates HTLV-1 p30II – mediated Repression of LTR Transcriptional Activity Virology 354:225-239, 2006.

Lairmore Laboratory Personnel

Contact
e-mail: lairmore.1@osu.edu
phone: 614-292-4489

207 Goss Laboratory
1925 Coffey Rd.,
Columbus
Ohio
43210

Links 
http://vet.osu.edu/MichaelLairmore.htm
http://vet.osu.edu/biosciences.htm
Department of Molecular Virology, Immunology, and Medical Genetics
Dorothy M. Davis Heart and Lung Research Institute (HLRI)
Comprehensive Cancer Center (CCC)